Catalyst Wire Dossier Catalyst Wire Dossier

PTX-022 (QTORIN Sirolimus)

sirolimus · Palvella Therapeutics, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for PTX-022 (QTORIN Sirolimus), covering 2025-01-17 to 2025-01-17. Get the full timeline:

Most recent: Clinical Trial Update: Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations [Phase 2]

See pricing